Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
Maru A, Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Matsumura Y, Nakagami Y, Niijima T, Obata K, et al. Maru A, et al. Among authors: kotake t. Cancer Chemother Pharmacol. 1987;20 Suppl:S44-8. doi: 10.1007/BF00262484. Cancer Chemother Pharmacol. 1987. PMID: 3311445 Clinical Trial.
Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group.
Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H, et al. Akaza H, et al. Among authors: kotake t. Cancer Chemother Pharmacol. 1987;20 Suppl:S91-6. doi: 10.1007/BF00262495. Cancer Chemother Pharmacol. 1987. PMID: 3117403 Clinical Trial.
Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
Obata K, Ohashi Y, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, et al. Obata K, et al. Among authors: kotake t. Cancer Chemother Pharmacol. 1994;35 Suppl:S88-92. doi: 10.1007/BF00686928. Cancer Chemother Pharmacol. 1994. PMID: 7994795 Clinical Trial.
[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K. Akaza H, et al. Among authors: kotake t. Gan To Kagaku Ryoho. 1997 May;24(7):829-36. Gan To Kagaku Ryoho. 1997. PMID: 9170521 Clinical Trial. Japanese.
Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group.
Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y. Akaza H, et al. Among authors: kotake t. Cancer Chemother Pharmacol. 1992;31(3):187-92. doi: 10.1007/BF00685546. Cancer Chemother Pharmacol. 1992. PMID: 1334448 Clinical Trial.
466 results